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Abstract 
High-throughput assays are important biological research tools but are rarely utilised for platelet 
research. However, screening compounds for efficacy against a physiologically relevant cellular 
response in primary cells such as platelets can be an advantageous approach to compound screening 
and drug development.  In this section we describe a panel of three high-throughput microtitre plate 
assays designed for platelets that can be used as the basis for compound screening, or be modified 
and used individually to increase throughput in platelet research labs. The platelet adhesion assay 
has the lowest requirement for platelet numbers and is therefore capable of the greatest 
throughput and so is suggested as the primary screen used to identify hits. A second screen against 
the ‘gold standard’ of platelet function, aggregation, is used to confirm and further characterise hits. 
Finally, a Ca2+ assay is used for initial mechanistic characterisation to begin the process of elucidating 
the mode of action of hit compounds. 
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1. Introduction 
Screening on the basis of clinically relevant functions using primary cells is referred to as 
physiological or phenotypic screening [1] and, by identifying compounds that exert a desired clinical 
effect on a target tissue, bypasses the need for initial target identification and screening using a cell 
line expressing a target protein [2]. Two functions of platelets that are relevant to their roles in 
thrombosis and haemostasis are their ability to adhere to proteins of the subendothelial matrix and 
to form aggregates. Mechanistic characterisation of compounds that are able to modulate these 
platelet functions should follow ‘hit’ identification to elucidate their mode of action. Cytosolic Ca2+ is 
a master regulator of platelet function and is common to nearly all platelet signalling pathways [3] 
and is therefore a versatile signalling output that can be used for initial mechanistic characterisation. 
This chapter describes a panel of high-throughput techniques to characterise the effects of 
compounds on three aspects of platelet function; adhesion, aggregation and Ca2+ signalling. The 
miniaturised platelet assays measure these outputs in microtiter plates and may be applied in 
sequence to screen compound libraries and to give comprehensive characterisation of ‘hits’ that 
modulate platelet function. Alternatively, the methods may be adapted and utilised individually to 
reduce costs, increase throughput and facilitate a pharmacological approach to platelet research. 
Platelet adhesion assays are commonly performed on glass coverslips coated in matrix proteins such 
as collagen. Our approach utilises 96-well microtitre plates, but the assay could easily be 
miniaturised for use in 384-well plates given the correct setup. The rationale behind using the 
platelet adhesion assay as the primary high-throughput screening test is the very low number of 
platelets required per test, at 1e6 platelets per well in a half-area 96-well plate or just 5e5 per well of 
a 384-well plate. Such low requirements are conducive to screening of compound libraries that may 
contain thousands of molecules. The challenges of the approach lie in data collection and analysis, as 
every well must be imaged and analysed to give a quantitative output of platelet adhesion and 
morphology. However, automated imaging platforms and bespoke analysis packages are now 
common and so capturing and analysing thousands of images is no longer the insurmountable 
challenge it once was. 
Platelet aggregometry has remained the gold standard in platelet function testing since the method 
was published by Gustav Born in 1963 [4]. Our plate-based aggregation assay was adapted from the 
method published by Lordkipanidze et al [5] and gives only an end-point measurement rather than 
the real-time aggregation trace generated by Born aggregometry. This means that only a single value 
is generated per condition tested giving a simplistic but easily interpretable read-out of platelet 
aggregation. Two advantages of the plate-based aggregation assay are that both the assay itself and 
the analysis are extremely quick. 
Ca2+ is a master regulator of platelet function, indeed elevation of cytosolic [Ca2+] is mediated 
downstream of almost all platelet activators and so it is also a point of signal integration. 
Measurement of cytosolic Ca2+ is a commonly utilised assay tool within the pharmaceutical industry 
and so specialised plate readers with automated liquid handling are similarly well established and 
also achieve good results when used to assay platelet responses. Our assay utilises half-area 96-well 
microtitre plates, but systems that enable rapid measurements of 384-well plates are also 
compatible with screening platelet responses. Ca2+ measurements are performed in real time and 
are therefore potentially more time consuming than other techniques described in this chapter. 
However, real time Ca2+ measurements reveal details of signalling dynamics that may be useful and 
can be used to inform quantitative systems pharmacology. 
High-throughput methodologies are increasingly being adopted within academia and while few 
academic labs have access to robotics and automated systems, facilities have been established that 
can give academic researchers access to high-throughput screening (HTS) platforms, compound 
libraries and specialists with expertise in HTS [6]. In addition to compound screening high 
throughput methodologies facilitate a pharmacological approach to the study of platelets by 
enabling concentration-response relationships to be defined quickly and easily. Estimation of IC50, 
EC50 and Emax values from platelet concentration response data, as well as other more complex 
pharmacological analysis have been outlined by Hourani [7]. Any attempts at compound screening 
and medicinal chemistry must include such pharmacological characterisation of compounds. Finally, 
high throughput methodologies facilitate testing of many different combinations of biologically 
active compounds, and therefore have many practical applications in research. 
  
2. Materials 
2.1. Buffers and solutions 
1. Tyrode’s buffer: 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 0.2 mM 
Na2HPO4, 12 mM NaHCO3, 5.5 mM D-glucose, [pH 7.4] 
2. Acid citrate dextrose (ACD): 29.9 mM trisodium citrate, 113.8 mM D-glucose, 
72.6 mM NaCl, and 2.9 mM citric acid [pH 6.4] 
3. Sodium citrate buffer: 10 mM trisodium citrate  
2.2. Reagents and equipment 
1. Half-area, clear, flat bottom 96 well microtiter plates (for aggregation assay) 
2. Half-area clear, flat bottom 96 well microtiter plates (for adhesion assay) 
3. Black, flat bottom half area 96-well microplates (for Ca2+ assay) 
4. Heated orbital plate shaker (capable of shaking at 1,200 rpm)  
5. Fluorescence microplate reader 
6. Absorbance microplate reader  
7. Confocal microscope 
8. Essentially fatty acid free bovine serum albumin 
9. 10% formalin solution 
10. 1mg/ml 3,3′-dihexyloxacarbocyanine iodide (DiOC6) 
11. Fura-2 AM 
3. Method 
3.1. Blood collection 
1. Obtain human blood from consenting healthy volunteers who are free of anti-
platelet medication and who have not taken painkillers (aspirin, ibuprofen or 
paracetamol) within 10 days, via venesection of the antecubital vein. Collect the 
blood into 3.8% (w/v) sodium citrate. 
3.2. Test compound preparation 
1. Prepare test compounds in 96-well ‘V’ or ‘U’-bottomed plates, deep-well plates 
may be used if volumes are sufficiently large 
2. Test compounds should be diluted in Tyrode’s buffer to 5 X final assay 
concentration. For example, for initial screening it may be appropriate to test 
compounds at 100µM, as so an intermediate dilution to 500µM should be 
prepared 
3. If a concentration range of test compound is to be tested, prepare half-log 
dilutions at 5 x final concentrations (e.g. 500, 150, 50, 15, 5µM etc.) in Tyrode’s 
buffer and include a vehicle control containing an equal concentration of solvent. 
The volume test-compound solution prepared should be equal to the volume 
required for all experiments plus a ‘dead volume’ of at least 20%. 
4. High-throughput adhesion assay 
4.1.1. Washed platelet preparation 
1. Add acid citrate dextrose (ACD) to a final concentration of 12.5% (v/v) and then 
centrifuge whole blood at 100g for 20 minutes and collect platelet rich plasma 
(PRP) into falcon tubes. Centrifuge PRP at 350g for 20 minutes, discard the 
supernatant and gently re-suspend platelet pellet in Tyrode’s buffer at a 
concentration of 2e7 platelets / ml 
4.2. Adhesion assay plate preparation 
1. Using a multichannel pipette, coat wells of 96-well, half area, clear bottom 
microtitre plate (referred to as ‘assay plate’) with 40µl of adhesive receptor 
ligand solution of choice for 1 hour at 37oC. Suitable proteins and peptides 
include collagen (100µg/ml), fibrinogen (100µg/ml), CRP-XL (10µg/ml) and 
GFOGER (10µg/ml). 
2. Aspirate ligand solution and wash once with Tyrode’s buffer 
3. Pipette 40µl of 1% BSA into assay plate and incubate for 1h at 37oC 
4. Aspirate BSA solution and wash three times with Tyrode’s buffer, if plate is not 
going to be used immediately, add 40µl of Tyrode’s buffer and use a plate sealer 
or lid to cover the plate and store at 4oC for no more than 24h 
4.2.2. Adhesion Assay 
1. Transfer 10µl of test compound solution to each well of the assay plate using a 
multichannel pipette, ensure that at least one well contains vehicle only, as all 
other conditions will be compared to the vehicle-treated sample 
2. Transfer washed platelet suspension to a reservoir and use a multichannel 
pipette to add 40µl to each well of the assay plate 
3. Cover and incubate for 45 minutes at 37OC 
4. Aspirate and discard washed platelet suspension and wash well once with 
Tyrode’s buffer, do not aspirate or dispense directly onto the centre of the well 
as this can dislodge adhered platelets. 
5. Add 40µl of 10% formalin solution to each well and incubate for 10 minutes at 
room temperature 
6. Aspirate and discard formalin solution and wash once with Tyrode’s buffer 
7. Add 40µl Tyrode’s buffer with 4µg/ml DiOC6 and incubate for 20 minutes at room 
temperature (there is no need to wash off the DiOC6) 
8. Either image immediately or store at 4oC for no more than 24h 
4.2.3. Imaging and analysis 
1. Either a microscope system with an automated, motorised stage or a high-
content imaging platform is highly recommended for image acquisition 
2. Fluorescence imaging should be performed using a 20X objective lens (note 1) 
using excitation at 488nm and measuring emission at 550nm 
3. Capture images with a resolution of at least 1024 x 1024 so that morphological 
characteristics of platelets can be distinguished  
4. Images should be captured in the centre of every well and exported as an image 
series to simplify analysis 
5. Many different image analysis packages are available and the exact method to 
identify, count and measure individual platelets will vary but usually involves: 
A) creating a ‘threshold’ that identifies platelets on the basis of fluorescence 
intensity (see note 2) and can be used to calculate % surface coverage 
which is the simplest output from the spreading assay (figure 1) 
B) using the binary image generated by the ‘threshold’ to perform object or 
particle measurements, whereby characteristics of platelets (such as 
number and spread area) are quantified (Figure 2A) 
C) The open source image analysis software, ImageJ or Fiji (Fiji Is Just ImageJ) 
can be used to analyse spreading data and a macro is included in the notes 
for this section (note 3), however, users are encouraged to gain familiarity 
with this software to ensure accurate results are achieved 
D) Once measurements of platelet area have been generated, scoring based 
on platelet area can be performed (figure 2) 
 
4.3. High-throughput aggregation assay 
4.3.1. Platelet preparation 
1. Either: 
A) For PRP, centrifuge whole blood at 100g for 20 minutes and collect PRP into 
falcon tubes (also collect 50µl of platelet poor plasma (PPP) for use as a 
‘blank’ per assay plate by centrifuging 60µl PRP at 10,000g for 2 minutes 
and aspirating 50µl of supernatant) 
B) For washed platelets, add acid citrate dextrose (ACD) to a final 
concentration of 12.5% (v/v) and then centrifuge whole blood at 100g for 
20 minutes and collect PRP into falcon tubes. Centrifuge PRP at 350g for 20 
minutes, discard the supernatant and gently re-suspend platelet pellet in 
Tyrode’s buffer at a concentration of 2e8 platelets / ml 
4.3.2. Aggregation assay 
1. Agonists should be prepared at 10 X final concentration is Tyrode’s buffer. For 
examples, if stimulation with 1µg/ml collagen (note 4) is required, prepare a 
sufficient volume of 10µg/ml collagen solution. 
2. Using a multichannel pipette, transfer 5µl of test compound to each well of a 
half-area, flat-bottom, clear 96-well microtitre plate (referred to as ‘assay plate’). 
3. Decant washed platelets or PRP into a reservoir and transfer 40µl into each well 
of the assay plate, avoid creating bubbles by using reverse pipetting (note 5) and 
incubate at room temperature for 5 minutes 
4. Add 40µl of Tyrode’s buffer or PPP plus 10µl of Tyrode’s buffer to one well of the 
assay plate to be used as a ‘blank’ 
5. Add 40µl of washed platelets or PRP to one well and add 10µl of Tyrode’s buffer, 
this will be the ‘resting’ sample 
6. Pre-heat plate shaker to 37OC and then securely clip assay plate onto the plate 
shaker 
7. Quickly and carefully add 5µl of 10 X agonist into the remaining wells of the assay 
plate (avoid bubbles), an electronic multichannel pipette with multi-dispense 
function makes this process quick and easy 
8. Shake plate at 1,200 rpm for 5 minutes 
9. Measure absorption (any wavelength of visible light should work) using a plate 
reader within 10 minutes 
4.3.3. Analysis 
1. Convert absorbance to % light transmittance (% LT) using the following equation: 
% 𝐿𝑇 = 10−𝐴𝑏𝑠 × 100 
2. Then convert % LT to % aggregation using this equation: 
% 𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑖𝑜𝑛 =
100
𝑅𝑒𝑠𝑡𝑖𝑛𝑔 − 𝐵𝑙𝑎𝑛𝑘
× 𝑥 − 𝐵𝑙𝑎𝑛𝑘 
Where ‘resting’ and ‘blanks are the% LT value for the resting and blank samples 
respectively and 𝑥 is the % LT value of a test sample 
3. If a concentration range of each test compound was tested, plot concentration 
response curves using curve fitting software to estimate IC50 and Emax values 
(figure 3) 
5. High-throughput Ca2+ assay 
5.1.1. Preparation of fura-2 loaded washed platelets 
1. Add acid citrate dextrose (ACD) to a final concentration of 12.5% (v/v) and then 
centrifuge whole blood at 100g for 20 minutes and collect PRP into falcon tubes 
2. Add fura-2 AM or other Ca2+ dye (note 6) for a final concentration of 2µM and 
incubate at 30oC for 1h 
3. Centrifuge PRP at 350g for 20 minutes, discard the supernatant and gently re-
suspend platelet pellet in Tyrode’s buffer at a concentration of 4e8 platelets / ml 
4. Store platelets at RT (note 7) and protect from light by wrapping falcon tube in 
aluminium foil 
5.1.2. Ca2+ Measurements 
1. Prepare agonist and test compound plates as described in the previous section, 
add  CaCl2 or EGTA at 10X final concentration to test compounds if assay needs to 
be performed with or without the contribution of store operated Ca2+ entry 
respectively (note 8) or omit these if the assay is to be performed under 
‘nominally Ca2+ free’ conditions (note 9). 
2. Turn on fluorescence plate reader 1h in advance of experiment to ensure it is at 
temperature 
3. Store assay plates at 37OC (in plate reader if possible) to enable them to 
equilibrate (note 10) 
4. Load 10µl of test compound (containing CaCl2 or EGTA) into as many wells as can 
be read simultaneously 
5. Add 80µl of fura-2 loaded platelets into the same wells 
6. Incubate at 37OC for 3 minutes 
7. Load next column / plate with test compounds and incubate at 37OC (this will 
allow these samples to reach 37OC while the other samples are measured) 
8. Use a measurement protocol with the following settings: 
A) Excitation at 340nm and 380nm 
B) Emission at 510nm 
C) Measure each well at least once every 4 seconds (note 11) 
D) 10µl of agonist injected at highest speed (see note 12) 20 seconds after 
measurement begins (Figure 4) 
E) Measure for a total duration of at least 2 minutes (see note 11) 
F) Data can be displayed  as a ratio of the fluorescence emission intensity 
excited by 380nm over 340nm, alternatively the [Ca2+] can be quantified 
using the method described by Ohlmann et al.[8] 
 
 
  
6. Notes 
1. Large images (acquired with a lower magnification objective lens) enable more accurate 
measurements by giving larger sample area but can compromise resolution and must be 
optimised for the system used for image acquisition. 
2. Thresholding must initially be performed manually but then should be not altered for consistency 
3. Basic FIJI macro for analysis of spreading data: 
run("Set Measurements...", "area mean area_fraction stack display add redirect=None decimal=3"); 
//run("Threshold..."); 
setAutoThreshold("Huang dark"); 
run("Convert to Mask", "method=Huang background=Dark"); 
run("Analyze Particles...", "size=20-200 display clear summarize stack"); 
4. Collagen is a versatile agonist in the context of platelet function screening because both adhesion 
to collagen and collagen-evoked aggregation are highly dependent on kinase signalling as well as 
signalling evoked by secreted secondary mediators such as ADP and TxA2. If a screening 
compound affects any of these processes, they will cause measurable inhibition collagen-
mediated platelet function. 
5. Reverse pipetting, whereby the volume aspirated into the pipette tip is greater than the volume 
to be dispensed, is critical to avoid creation of bubbles in PRP when performing the aggregation 
assay. Bubbles cause major artefacts when light transmittance is measured. To reverse pipette; 
push the pipette plunger to the ‘second stop’ and the carefully aspirate liquid until the plunger is 
back in the starting position. Transfer liquid to the recipient well by pressing the plunger down to 
the ‘first stop’. The liquid remaining in the tip can be discarded, returned to the original well or 
another transfer of the same liquid can be performed without dispensing the residual liquid. 
6. Many non-ratiometric Ca2+ dyes, such as fluo 4 and fluo 4 can be used to measure intracellular 
Ca2+ in platelets and excitation and emission filters for the appropriate wavelengths are more 
likely to be included with non-specialist plate readers. However, agonist addition artefacts 
cannot be compensated for by non-ratiometric dyes and can complicate data analysis. 
7. Storage of Fura-2 loaded platelets at RT is preferable to storage at 37OC as leakage of Ca2+ dyes 
is temperature dependent, therefore warm to 37OC only immediately prior to measurement 
8. If it is desirable to perform Ca2+ measurements experiments in the presence of extracellular Ca2+ 
or EGTA, these should be combined with test compounds and pre-incubated with platelets for no 
longer than 5-10 minutes to avoid spontaneous platelet activation or depletion of intracellular 
Ca2+ stores respectively. 
9. It should be noted that unless a Ca2+ chelator is added to assay buffer, the buffer cannot be truly 
free of Ca2+ due to contamination of other salts with Ca2+-containing salts and is instead referred 
to as ‘nominally Ca2+ free’ 
10. Ca2+ measurements are extremely sensitive to temperature so it is critical to ensure proper 
equilibration to 37oC prior to agonist stimulation in order to achieve reproducible results 
11. Ca2+ release can occur very rapidly, especially when evoked by GPCRs, and so care should be 
taken to ensure that a reading is taken from each well at least every 4 seconds. However, some 
responses (e.g. to collagen) occur slowly and total measurement time may need to be increased 
to capture the peak of the response. 
12. As Ca2+ assays performed in microtitre plates cannot be performed under stirring conditions, 
mixing of agonists with the platelet suspension is dependent on the speed of agonist injection. 
Agonist injection speed should therefore be set to a high setting to achieve complete mixing.  
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Figure 1. Measurements of platelet surface coverage on fibrinogen. Washed platelet were treated 
with inhibitors at a range of concentrations and then incubated at room temperature for 45 minutes 
in fibrinogen coated wells of a 96-well plate and then fixed and stained with DiOC6. A) 
Representative images of fibrinogen adhered platelets treated with integrin αIIbβ3 antagonist, 
integrillin or vehicle. B) Platelet adhesion quantified in terms of % surface coverage and plotted 
against inhibitor concentration and fitted using non-linear regression. Only integrillin is able to 
ablate adhesion of platelets to fibrinogen while cangrelor, dasatinib and ibrutinib are partial 
inhibitors. 
  
  
  
Figure 2. High content analysis of spreading on different coatings. Washed platelet were treated 
with ibrutinib at a range of concentrations and then incubated at room temperature for 45 minutes 
in fibrinogen, CRP-XL or collagen coated wells of a 96-well plate and then fixed and stained with 
DiOC6. Wells were imaged and then the area of individual platelets was estimated and used to ‘bin’ 
platelets into categories corresponding to the presence of the following morphological 
characteristics; Lamellipodia, filopodia or adhered only. A) Representative images of platelets fitting 
into these categories and binary images used to estimate their area. Numbers of platelets in each 
category were plotted against [ibrutinib] for platelets adhered to B) CRP-XL, C) collagen and D) 
fibrinogen. High content analysis highlights important differences in the way that ibrutinib 
modulates platelet adhesion and spreading on different adhesive surfaces. 
  
  
Figure 3. Test compound titrations and log IC50 values.  Washed platelets were treated with a range 
of inhibitor concentrations (100µM to 100nM at half-log intervals). Platelets were stimulated with 
1µg/ml collagen and shaken for 5 minutes. Log IC50 values were estimated from non-linear 
regression analysis, although concentration ranges of some compounds could be adjusted in 
subsequent experiments. Stimulating with a low concentration of collagen is useful for screening as 
aggregation under these conditions is highly dependent on tyrosine kinases such as SFKs and Syk as 
well as the contribution of receptors activated by secreted agonists such as ADP. Consequently 
inhibition caused by dasatinib (SFK inhibitor), entospletinib (Syk inhibitor) and MRS2179 (P2Y1 
antagonist) as well as several other inhibitors with diverse functions is easily detected.  
 
  
  
Figure 4. Simultaneous Ca2+ measurements stimulated by a range of CRP-XL concentrations. Fura-2 
loaded washed platelets were stimulated with CRP-XL (between 10µg/ml to 0.01 µg/ml at half-log 
intervals) in a 96-well plate. Agonist was injected into 8-wells and fluorescence measured 
simultaneously for 200s. 
  
 Figure 5. Inhibitor combinations to study relative contributions of secreted secondary mediators 
to CRP-XL evoked Ca2+ signalling and regulation by Btk, Syk and PI3K. Fura-2 loaded washed 
platelets in the presence or absence of secondary mediator inhibitor cocktail (100µM MRS2179, 
1µM Cangrelor and 10µM indomethacin) were treated with a range of concentrations of A) Ibrutinib, 
B) PRT062607 or C) Alpelisib (between 10µM to 0.01 µM at half-log intervals) and stimulated with 1 
µg/ml CRP-XL in a 96-well plate. Agonist was injected into 8-wells and fluorescence measured 
simultaneously for 300s. Ibrutinib and PRT062607 inhibit Ca2+ signalling with equal potency in the 
presence or absence of the inhibitor cocktail, while Alpelisib is a more potent inhibitor of the portion 
of Ca2+ signalling contributed by secreted secondary mediators. 
 
 Figure 6. Pipetting into microtiter plates. When pipetting into microtitre plates A) angle the pipette 
tips into the corner of the well and make contact with one of the walls and avoid B) touching the 
pipette tip at a right-angle to the bottom of the well which may block the opening or C) failing to 
touch the edge of the well which may cause drops to be retained on the pipette tip. 
 
 
 
